MedTrace Logo

Effect of Sitagliptin on Postprandial Lipoprotein Metabolism

NCT00939939 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2011-06-27

No results posted yet for this study

Summary

The goal of the study is to evaluate whether sitagliptin can affect postprandial lipoprotein metabolism in type 2 diabetic patients.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

sitagliptin

sitagliptin 100 mg/d for 10 weeks

DRUG

glimepiride

glimepiride 1 mg/d for 10 weeks

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939939 on ClinicalTrials.gov